Donor HLA-specific Abs: To BMT or not to BMT?

Bone Marrow Transplantation

Volumn 50, Issue 6, 2015, Pages 751-758

  Leffell, M S ^a   Jones, R J ^b   Gladstone, D E ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOPHOSPHAMIDE; DONOR SPECIFIC HLA ANTIGEN; FILGRASTIM; FLUDARABINE; HLA ANTIGEN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; ALLOANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; APLASTIC ANEMIA; BLOOD GROUP TYPING; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; DESENSITIZATION; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SICKLE CELL ANEMIA; T CELL LYMPHOMA; ALLOGRAFT; DONOR; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY;

ALLOGRAFTS; BONE MARROW TRANSPLANTATION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; TISSUE DONORS;

EID: 84930374530     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.331     Document Type: Review

References (36)

1. Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 124: 334-343
2. Fuchs E, O'Donnell PV, Brunstein CG. Alternative transplant donor sources: Is there any consensus?. Curr Opin Oncol 2013; 25: 173-179
3. Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unkowns, and controversies. Biol Blood Marrow Transplant 2013; 19: 180-184
4. Cutler C, Ballen KK. Improving outcomes in umbilical cord blood transplantation: state of the art. Blood Rev 2012; 26: 241-246
5. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012; 18: 1036-1043
6. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650
7. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with highdose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482-489
8. Brand A, Doxiadis IN, Roelen DL. On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 2013; 81: 1-11
9. Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 47: 508-515
10. Fernandez-Vina MA, de Lima M, Ciurea SO. Humoral sensitization matters in CBT outcome. Blood 2011; 118: 6482-6484
11. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957-5964
12. Fancosi D, Zucca A, Scatena F. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1585-1588
13. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118: 6691-6697
14. Spellman S, Bray R, Ronsen-Bronsen S, Haagenson M, Klein J, Flesh S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704-2708
15. Ciurea SO. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019-1024
16. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204
17. Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011; 17: 1704-1708
18. Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, et al. The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS ONE 2013; 8: e72141
19. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donorspecific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Francaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica 2013; 98: 1154-1160
20. Gladstone DE, Zachary AA, Fuchs EJ, Luznik YL, King KE, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013; 19: 647-652
21. Costa LJ, Moussa O, Bray RA, Stuart RK. Overcoming HLA-DPB1 donor specific antibody-mediated hematopoietic graft failure. Br J Haematol 2010; 151: 84-109
22. Norlander A, Uhlin M, Ringden O, Kumlien G, Hausenberger D, Mattsson J. Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. Transplant Immunol 2011; 25: 153-158
23. Ishiyama K, Anzai N, Tashima M, Hayashi K, Saji H. Rapid hematopoietic recovery with high levels of DSA in an unmanipulated haploidentical transplant patient. Transplantation 2013; 95: e76-e77
24. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. Immunol Rev 2014; 258: 183-207
25. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-328
26. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70: 496-501
27. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574-579
28. Montgomery RA, Zachary AA. Transplanting patients with a positive donorspecific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535-542
29. Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165-171
30. Guthoff M, Schmid-Horch B, Wiesel KC, Häring HU, Königsrainer A, Heyne M. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012; 26: 171-175
31. Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012; 93: 572-577
32. Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. Transplantation 2014; 98: 660-665
33. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370
34. Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, Montgomery RA, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9: 2136-2139
35. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116: 2839-2846
36. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47